Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Phase 1 Completed 101 enrolled Astex Pharmaceuticals, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.

Timeline

Start: 2007-11
Primary completion: 2009-12
Completion: 2009-12

Publications

Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. doi: 10.1007/s00280-014-2481-1. Epub 2014 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amuvatinib	Small molecule	—	Oral
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Erlotinib	Small molecule	150 mg	Oral
Background	Etoposide	Small molecule	100 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	200 mg/m2	Intravenous
Background	Topotecan	Small molecule	1.5 mg/m2	Intravenous

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Summary

Timeline

Publications

Drugs

Indications